Hong Kong-based CK Life Sciences International (Holdings) Inc. has increased its holdings of restricted voting shares of Vancouver's WEX Pharmaceuticals Inc. (TSX:WXI).The acquisition was made through the conversion by a wholly-owned subsidiary of CK Life of a $15.6 million convertible debenture of WEX, which conducts research on pain management drugs.CK Life acquired 116.8 million restricted voting shares based on a share price of $0.1409 per share. CK Life also received 6.1 million shares at $0.2083 per share in lieu of accrued but unpaid interest on the amounts outstanding under the debenture.CK Life said its increased equity stake was a strategic investment and may alter its holdings depending on the business and prospect of WEX or CK Life.WEX's share price range during the past week: between $0.185 and $0.215; 52-week high: $0.46: 52-week low: $0.12.